Get the Stockscreener App
1.11
1.77%
-0.02
After Hours:
1.13
0.02
+1.80%
Humacyte Inc stock is traded at $1.11, with a volume of 4.59M.
It is down -1.77% in the last 24 hours and down -15.27% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.13
Open:
$1.13
24h Volume:
4.59M
Relative Volume:
0.92
Market Cap:
$214.23M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.0374
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+2.78%
1M Performance:
-15.27%
6M Performance:
-51.95%
1Y Performance:
-74.72%
1-Day Range:
$1.08
$1.15
1-Week Range:
$1.08
$1.25
52-Week Range:
$0.91
$4.85
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.11 | 218.09M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Analyst Upgrade: Can Humacyte Inc. stock maintain growth trajectoryTrade Signal Summary & Weekly Momentum Picks - moha.gov.vn
CEO Moves: What catalysts could drive Humacyte Inc. stock higherPortfolio Risk Report & Fast Gain Stock Tips - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA): Are Analysts Optimistic? - Yahoo Finance UK
Quarterly Risk: Does Humacyte Inc Equity Warrant stock benefit from AI growthPortfolio Return Report & Verified Swing Trading Watchlists - baoquankhu1.vn
While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most - simplywall.st
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Is Humacyte Inc. Equity Warrant stock undervalued vs historical averagesTrail vs Road Selection & quick comparison of popular models - ulpravda.ru
How buybacks impact Humacyte Inc. Equity Warrant stock valueJuly 2025 Gainers & Entry Point Confirmation Alerts - ulpravda.ru
Will Humacyte Inc. Equity Warrant stock gain from lower inflationPortfolio Gains Report & Fast Gaining Stock Reports - ulpravda.ru
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 571.55% Upside in the Biotech Sector - DirectorsTalk Interviews
Is Humacyte Inc. Equity Warrant stock a contrarian buyQuarterly Growth Report & Real-Time Volume Spike Alerts - ulpravda.ru
Will Humacyte Inc. stock recover faster than peersJuly 2025 Movers & Reliable Intraday Trade Alerts - ulpravda.ru
Can Humacyte Inc. Equity Warrant stock resist market sell offsOptions Play & Fast Gain Swing Trade Alerts - ulpravda.ru
Winners Losers: Can Humacyte Inc. stock deliver sustainable ROE2025 Sector Review & AI Enhanced Trading Alerts - ulpravda.ru
Form 8-KCurrent report - ADVFN
What sentiment indicators say about Humacyte Inc. stockMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Can Humacyte Inc. stock sustain revenue growthJuly 2025 Volume & Verified Chart Pattern Trade Signals - ulpravda.ru
How strong is Humacyte Inc. Equity Warrant stock revenue growthMarket Performance Report & Precise Buy Zone Identification - ulpravda.ru
Can Humacyte Inc. stock deliver sustainable ROEQuarterly Market Summary & AI Driven Stock Reports - ulpravda.ru
Today's Analyst Ratings: Humacyte (HUMA) Maintains "Buy" Rating - GuruFocus
Preventable surgery complications can drive hospital charges toward $600K - Stock Titan
Patterns Watch: Can Humacyte Inc stock deliver sustainable ROESwing Trade & Risk Managed Investment Signals - moha.gov.vn
Humacyte, Inc.Common Stock (NQ: HUMA - FinancialContent
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - marketscreener.com
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - marketscreener.com
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com South Africa
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Humacyte, Inc. (HUMA) Stock Analysis: Exploring A Potential 718% Upside In Biotechnology - DirectorsTalk Interviews
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Is Humacyte, Inc. (HUMAW) Stock Down Today? - Meyka
Can Humacyte Inc. Equity Warrant stock maintain growth trajectoryChart Pattern Recognition & Compound Your Gains With Quality Stocks - Bollywood Helpline
Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Humacyte Reports High Limb Salvage Rates and Durability of Symvess in Long-Term Study Published in JVS-CIT - Quiver Quantitative
Off-the-shelf blood vessel implant helps save injured limbs in study - Stock Titan
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Regulatory Ruptures For A Lab-Grown Blood Vessel - The Lever
Humacyte terminates revenue interest agreement - MSN
Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - bolumsonucanavari.com
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Humacyte, Inc. (HUMA) Stock Analysis: Biotechnology Visionary with a 607.85% Potential Upside - DirectorsTalk Interviews
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - ulpravda.ru
Published on: 2025-12-19 01:36:49 - Улправда
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
2.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):